id.DRIVE
A public-private partnership to facilitate the conduct of observational studies on infectious diseases, vaccines, related preventive measures, therapeutics and diagnostics in Europe.
Interested in important updates on the partnership?
Subscribe to our newsletter by contacting us
WHAT IS id.DRIVE?
id.DRIVE is a privately funded not-for-profit public-private partnership that facilitates the conduct of infectious diseases studies on vaccines, related preventive measures, therapeutics and diagnostics in the European region. These studies support the region’s public health response and address pharmaceutical companies’ regulatory obligations. This multi-stakeholder partnership brings together public institutions, small and medium sized enterprises (SMEs) and pharmaceutical companies.
id.DRIVE is launched in 2024 as the successor of COVIDRIVE, a public-private partnership that was set-up during the COVID-19 pandemic to perform COVID-19 Vaccine Effectiveness studies. id.DRIVE expands the scope of COVIDRIVE beyond COVID-19 and will study many different infectious diseases. id.DRIVE leverages the IMI funded DRIVE Influenza Vaccine Effectiveness platform (link).
id.DRIVE is open to new Partners and Study Contributors.
VISION AND MISSION
JOINING FORCES TOWARDS A BETTER UNDERSTANDING AND PREVENTION OF INFECTIOUS DISEASES, VACCINES AND THERAPEUTICS
To jointly develop methodological and technical resources to undertake infectious diseases studies in Europe.
To conduct large scale multi-centre observational studies.
To leverage established public health capacities and optimize health care professional resources in large data collections supporting multiple studies.
To build a sustainable partnership by establishing and maintaining a rich scientific community, central data sharing and analysis platform, supporting study documents and regulatory communication.
Scope
The partnership intends to conduct studies on infectious diseases, vaccines, related preventive measures, therapeutics and diagnostics. The Studies might fall under the following scope:
Burden of disease, including impact on health care utilisation.
Effectiveness of vaccines, related preventive measures, therapeutics and diagnostics for infectious diseases.
Impact of vaccination and related infectious diseases prevention programs and therapeutics treatments.
PARTNERS
FISABIO (Spain)
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
P95 (Belgium)
Excellence in pharmacovigilance and Epidemiology
AstraZeneca
(United Kingdom)
Novavax
(United States)
GlaxoSmith Kline
(Belgium)
Janssen
(Belgium)
Valneva
(France)
Pfizer
(United States)
